Good resistance of the 2020/2021 revenues: -1%. Confirmation of
profitability objectives for fiscal year 2020/2021 and a return to
double-digit growth in the current fiscal year
PRESS RELEASE
Paris, April 28, 2021
Good resistance of the 2020/2021 revenues:
-1%
Confirmation of
profitability objectives for fiscal year 2020/2021 and a
return to double-digit growth in the current fiscal
year
Generix Group,
Industrial, Logistics and Retail Ecosystems provider with leading
Collaborative SaaS Solutions, issued today its revenues for its
2020/2021 fiscal year.
2020/2021 revenues:
Good resistance and
record-breaking last quarter
|
|
Quarter ended March 31 |
Change |
12 months ended March 31 |
Change |
| Unaudited (K€) |
2021 |
2020 |
2021 |
2020 |
|
SaaS |
8 180 |
7 986 |
2% |
32 252 |
32 402 |
0% |
|
Maintenance |
4 562 |
4 683 |
-3% |
18 051 |
19 199 |
-6% |
|
Licenses |
1 412 |
915 |
54% |
4 246 |
3 715 |
14% |
|
Software revenues |
14 154 |
13 584 |
4% |
54 549 |
55 316 |
-1% |
| Consulting Services |
7 265 |
6 834 |
6% |
25 707 |
25 779 |
0% |
|
Revenues |
21 419 |
20 418 |
5% |
80 256 |
81 095 |
-1% |
Reclassification of €193K over the quarter and
€885K over the fiscal year, as Consulting and Services revenue,
concerning services previously accounted for as Maintenance
revenue. After reprocessing this reclassification, Maintenance
revenue showed a slight growth in Q4 (+2%) and a slight drop in YTD
(-1%), primarily as a result of the temporary suspension of
contracts during the lockdown period. Consulting and Services
revenue, which is by nature more vulnerable in the current context,
showed a +3,5% growth over Q4 and a -4% drop in YTD.
For the 2020/2021 fiscal year, the Group's
revenues came to €80.3m (-1%) at current exchange rates, and
€81.9m, up 1% at constant exchange rates, driven in particular by a
34% organic increase in revenues generated in North America.
Over the last quarter of the year, in a still
difficult global health climate, Generix Group set a new quarterly
revenue record at €21.4 million, up 5% on the same period of the
previous year (7.1% at constant exchange rates).
Growth over the quarter was mainly driven
by:
-
sustained license sales activity (+54%), particularly in North
America (x3) and France (+40%);
-
growth in consulting and services activities, particularly in North
America (+36%).
Q4 New SaaS contract
signing: €
2,2M
(+86%)
|
|
Quarter ended March 31 |
Var. Q4 2021 vs Q4 2020 |
12 months ended March 31 |
Var. 2021 vs 2020 |
| Unaudited (K€) |
2021 |
2020 |
2021 |
2020 |
|
New SaaS contract signing (ACV*) |
2 217 |
1 191 |
86% |
4 746 |
3 552 |
34% |
*New contracts signed expressed in ACV (Annual
Contract Value), emphasize the average annual complementary revenue
to be generated after implementing the contracts in question.
In addition to the good momentum of license
sales, the past quarter was also marked by the confirmation of a
return to a sustained rate of new SaaS contract signatures (+86%).
This trend more than offsets the decline in signatures in the first
half of the year. Over 12 months, signing of SaaS contracts
increased by 34%.
Among the new SaaS signatures on the Generix
Supply Chain Hub platform, the following should be noted:
-
a contract in Russia for five new WMS sites for a world leader in
the food industry, which Generix Group is supporting in its
international deployment;
-
a contract in Spain concerning four new warehouses for a leading
DIY retailer.
Over the year, the Group signed €4.7 million
(+34%) in new contracts, enabling it to generate 6% growth in
CMRR*.
Confirmation of
profitability objectives for fiscal year
2020/2021
Return to double-digit
growth in the current fiscal year
The level of revenues recorded over the past
quarter enables the Group to confirm the expected trend in
profitability for the 2020/2021 financial year, which should be in
line with that observed in the first half of the year, with a
controlled decline in the EBITDA margin, excluding the impact of
the effort made in research and development.
Generix Group expects to maintain a sustained
rate of new SaaS contract signatures over the coming quarters,
which should enable it to return to double-digit revenue growth as
early as in 2021/2022.
The rapid recovery seen in the last quarter of
the year demonstrates that Generix Group's solutions are well
suited to the customer needs revealed by the crisis. As announced,
the Group intends to pursue its strategic investments in R&D in
order to benefit from the full potential of the supply chain and
digitalization markets.
* Monthly recurring revenue after taking into
account contracts that are signed but which have not started yet
and cancel-lations that have not yet taken effect.
Supplemental
and non-IFRS Financial Information
Supplemental non-IFRS
information (above-mentioned as EBITDA) presented in this press
release is subject to inherent limitations. It is not based on any
comprehensive set of accounting rules or principles and should not
be considered as a substitute for IFRS measurements. Also, the
Company’s supplemental non-IFRS financial information may not be
comparable to similarly titled non-IFRS measures used by other
companies.
Next financial press release: June 2, 2021 after
the market closes
Publication of results for the 2020/2021 fiscal
year
About Generix
Group
Generix Group
is a Collaborative Supply Chain expert present in 60 countries,
thanks to its subsidiaries and network of partners. More than 6,000
companies around the world use its SaaS solutions. The group’s 750
employees provide daily support for such customers as Carrefour,
Danone, FM Logistic, Fnac-Darty, Essilor, Ferrero and Geodis in the
digital transformation of their Supply Chain.
Its collaborative platform,
Generix Supply Chain Hub, helps
companies to keep the promises they make to their customers. It
combines the capabilities to execute physical flows, digitalize
information flows, manage collaborative processes and connect
companies to all their partners, in real time.
Generix Supply Chain
Hub is aimed at all players in the Supply Chain:
manufacturers, third- and fourth-party logistics providers
(3PL/4PL) and retailers.
www.generixgroup.com
Founded in France in 1990, the company is listed on
the Eurolist market of Euronext Paris, compartment C (ISIN:
FR0010501692). To learn more: www.generixgroup.com
- EXT-EN-FINA-PR-REV-Q4-2020-2021